Which way for drug-mediated immunosuppression?

Vijay K. Sharma, Baogui Li, Ashwani Khanna, Prabodh K. Sehajpal, Manikkam Suthanthiran

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The basic immunosuppressive protocol involves the use of multiple drugs, each directed at a discrete site in the T-cell activation cascade. The prevailing paradigm regarding the mechanisms of action of immunosuppressants is that they function to prevent allograft rejection by preventing cell activation, proliferation and/or cytokine production. A new hypothesis is that some of the immunosuppressants might function by stimulating the expression of immunosuppressive molecules and/or cells.

Original languageEnglish
Pages (from-to)784-790
Number of pages7
JournalCurrent Opinion in Immunology
Volume6
Issue number5
DOIs
Publication statusPublished - 1 Jan 1994
Externally publishedYes

Fingerprint

Immunosuppressive Agents
Immunosuppression
Pharmaceutical Preparations
Allografts
Cell Proliferation
Cytokines
T-Lymphocytes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Which way for drug-mediated immunosuppression? / Sharma, Vijay K.; Li, Baogui; Khanna, Ashwani; Sehajpal, Prabodh K.; Suthanthiran, Manikkam.

In: Current Opinion in Immunology, Vol. 6, No. 5, 01.01.1994, p. 784-790.

Research output: Contribution to journalArticle

Sharma, Vijay K. ; Li, Baogui ; Khanna, Ashwani ; Sehajpal, Prabodh K. ; Suthanthiran, Manikkam. / Which way for drug-mediated immunosuppression?. In: Current Opinion in Immunology. 1994 ; Vol. 6, No. 5. pp. 784-790.
@article{3134b2bd09754562bc3487261939d3b3,
title = "Which way for drug-mediated immunosuppression?",
abstract = "The basic immunosuppressive protocol involves the use of multiple drugs, each directed at a discrete site in the T-cell activation cascade. The prevailing paradigm regarding the mechanisms of action of immunosuppressants is that they function to prevent allograft rejection by preventing cell activation, proliferation and/or cytokine production. A new hypothesis is that some of the immunosuppressants might function by stimulating the expression of immunosuppressive molecules and/or cells.",
author = "Sharma, {Vijay K.} and Baogui Li and Ashwani Khanna and Sehajpal, {Prabodh K.} and Manikkam Suthanthiran",
year = "1994",
month = "1",
day = "1",
doi = "10.1016/0952-7915(94)90085-X",
language = "English",
volume = "6",
pages = "784--790",
journal = "Current Opinion in Immunology",
issn = "0952-7915",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Which way for drug-mediated immunosuppression?

AU - Sharma, Vijay K.

AU - Li, Baogui

AU - Khanna, Ashwani

AU - Sehajpal, Prabodh K.

AU - Suthanthiran, Manikkam

PY - 1994/1/1

Y1 - 1994/1/1

N2 - The basic immunosuppressive protocol involves the use of multiple drugs, each directed at a discrete site in the T-cell activation cascade. The prevailing paradigm regarding the mechanisms of action of immunosuppressants is that they function to prevent allograft rejection by preventing cell activation, proliferation and/or cytokine production. A new hypothesis is that some of the immunosuppressants might function by stimulating the expression of immunosuppressive molecules and/or cells.

AB - The basic immunosuppressive protocol involves the use of multiple drugs, each directed at a discrete site in the T-cell activation cascade. The prevailing paradigm regarding the mechanisms of action of immunosuppressants is that they function to prevent allograft rejection by preventing cell activation, proliferation and/or cytokine production. A new hypothesis is that some of the immunosuppressants might function by stimulating the expression of immunosuppressive molecules and/or cells.

UR - http://www.scopus.com/inward/record.url?scp=0028148355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028148355&partnerID=8YFLogxK

U2 - 10.1016/0952-7915(94)90085-X

DO - 10.1016/0952-7915(94)90085-X

M3 - Article

VL - 6

SP - 784

EP - 790

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

SN - 0952-7915

IS - 5

ER -